Mij
Senior Member (Voting Rights)
Moderna is eyeing a new target: long Covid.
The pharmaceutical company that became a household name when it developed a Covid-19 vaccine now wants to treat the disease’s lingering effects, which have afflicted tens of millions of people by some estimates.
“We see this as an opportunity for Moderna to repeat our leadership and our expertise,” Bishoy Rizkalla, the company’s vice president of long Covid, told Daniel.
LINK
The pharmaceutical company that became a household name when it developed a Covid-19 vaccine now wants to treat the disease’s lingering effects, which have afflicted tens of millions of people by some estimates.
“We see this as an opportunity for Moderna to repeat our leadership and our expertise,” Bishoy Rizkalla, the company’s vice president of long Covid, told Daniel.
LINK